Skip to content

Randomized controlled clinical trial of the safety and efficiency of Regional citrate anticoagulation versus traditional anticoagulation modes for CRRT in liver failure patients with AKI

Randomized controlled clinical trial of the safety and efficiency of Regional citrate anticoagulation versus traditional anticoagulation modes for CRRT in liver failure patients with AKI

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084062
Enrollment
Unknown
Registered
2024-05-09
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver failure complicated with acute kidney injury

Interventions

Regional citrate anticoagulation:Patients appling regional citrate anticoagulation during CRRT
traditional anticoagulation:Patients appling traditional anticoagulation during CRRT

Sponsors

The First Affiliated Hospital of the Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 years old; 2.liver failure: Acute liver failure (including chronic acute): hepatic coma (if the patient has other causes related to impaired consciousness, a comprehensive judgment can be made based on test indicators), PTA (prothrombin activity) 85.5 micromol/L (or daily increase = 17.1 micromol/L); Chronic liver failure: Child-Pugh score =10, or INR >1.5 (no anticoagulation), or PTA (prothrombin activity) 51 micromol/L (3 times the upper limit of normal); 3.Have an indication for CRRT treatment and are willing to accept CRRT treatment; 4.Willing to participate in this study and sign the informed consent form

Exclusion criteria

Exclusion criteria: 1. Non-renal replacement therapy reasons require systemic anticoagulation (heparin/low molecular/warfarin, etc.); 2. Patients who are pregnant or breastfeeding; 3. Uncorrectable lactic acidosis (pH 2 hours, and lactate >8mmol/L); 4. Patients treated with CRRT for internal fistula; 5. Pre-existing heparin-induced thrombocytopenia; 6. Known allergy to a certain anticoagulant

Design outcomes

Primary

MeasureTime frame
patients survival time;filter lifespan;

Secondary

MeasureTime frame
bleeding;Kidney recovery;Filter transmembrane pressure;CRRT-related complications;

Countries

China

Contacts

Public ContactShiren Sun

The First Affiliated Hospital of the Air Force Medical University

sunshiren@medmail.com.cn+86 136 7922 0706

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026